|
Originally published In Press as doi:10.1074/jbc.M500523200 on January 28, 2005
J. Biol. Chem., Vol. 280, Issue 15, 14918-14922, April 15, 2005
Cholesteryl Ester Transfer Protein Variants Have Differential Stability but Uniform Inhibition by Torcetrapib*
David B. Lloyd ,
Maruja E. Lira ,
Linda S. Wood ,
L. Kathryn Durham ,
Thomas B. Freeman¶,
Gregory M. Preston¶,
Xiayang Qiu||,
Eliot Sugarman**,
Peter Bonnette**,
Anthony Lanzetti||,
Patrice M. Milos , and
John F. Thompson 
From the
Departments of Discovery Pharmacogenomics, Clinical Biostatistics, ¶Translational Biomarkers, ||Protein Expression and Structure, and **Cardiovascular and Metabolic Diseases, Pfizer Global Research and Development, Groton, Connecticut 06340
Cholesteryl ester transfer protein (CETP) is an important modulator of high density lipoprotein cholesterol in humans and thus considered to be a therapeutic target for preventing cardiovascular disease. The gene encoding CETP has been shown to be highly variable, with multiple single nucleotide polymorphisms responsible for altering both its transcription and sequence. Examining nine missense variants of CETP, we found some had significant associations with CETP mass and high density lipoprotein cholesterol levels. Two variants, Pro-373 and Gln-451, appear to be more stable in vivo, an observation mirrored by partial proteolysis studies performed in vitro. Because these naturally occurring variant proteins are potentially present in clinical populations that will be treated with CETP inhibitors, all commonly occurring haplotypes were tested to determine whether the proteins they encode could be inhibited by torcetrapib, a compound currently in clinical trials in combination with atorvastatin. Torcetrapib behaved similarly with all variants, with no significant differences in inhibition.
Received for publication, January 14, 2005
* The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
 To whom correspondence should be addressed: MS8118D-3069, Eastern Point Rd., Pfizer Global Research and Development, Groton, CT 06340. Tel.: 860-441-5139; Fax: 860-441-0436; E-mail: john.f.thompson{at}pfizer.com.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
M. E. Lira, A. K. Loomis, S. A. Paciga, D. B. Lloyd, and J. F. Thompson
Expression of CETP and of splice variants induces the same level of ER stress despite secretion efficiency differences
J. Lipid Res.,
September 1, 2008;
49(9):
1955 - 1962.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Thompson, E. Di Angelantonio, N. Sarwar, S. Erqou, D. Saleheen, R. P. F. Dullaart, B. Keavney, Z. Ye, and J. Danesh
Association of Cholesteryl Ester Transfer Protein Genotypes With CETP Mass and Activity, Lipid Levels, and Coronary Risk
JAMA,
June 18, 2008;
299(23):
2777 - 2788.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. A. Morehouse, E. D. Sugarman, P.-A. Bourassa, T. M. Sand, F. Zimetti, F. Gao, G. H. Rothblat, and A. J. Milici
Inhibition of CETP activity by torcetrapib reduces susceptibility to diet-induced atherosclerosis in New Zealand White rabbits
J. Lipid Res.,
June 1, 2007;
48(6):
1263 - 1272.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. F. Thompson, L. S. Wood, E. H. Pickering, B. DeChairo, and C. L. Hyde
High-density genotyping and functional SNP localization in the CETP gene
J. Lipid Res.,
February 1, 2007;
48(2):
434 - 443.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Gauthier, P. Lau, X. Zha, R. Milne, and R. McPherson
Cholesteryl Ester Transfer Protein Directly Mediates Selective Uptake of High Density Lipoprotein Cholesteryl Esters by the Liver
Arterioscler. Thromb. Vasc. Biol.,
October 1, 2005;
25(10):
2177 - 2184.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2005 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|